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Patients with inborn errors of interleukin-17F (IL-17F)
or IL-17RA display chronic mucocutaneous candidi-
asis (CMC). We report a biallelic missense mutation
(T536I) in the adaptor molecule ACT1 in two siblings
with CMC. The mutation, located in the SEFIR
domain, abolished the homotypic interaction of
ACT1 with IL-17 receptors, with no effect on homo-
dimerization. The patients’ fibroblasts failed to
respond to IL-17A and IL-17F, and their T cells to
IL-17E. By contrast, healthy individuals homozygous
for the common variant D10N, located in the ACT1
tumor necrosis factor receptor-associated factor-
interacting domain and previously associated with
psoriasis, had impaired, but not abolished, re-
sponses to IL-17 cytokines. SEFIR-independent in-
teractions of ACT1 with other proteins, such as
CD40, heat shock protein 70 (HSP70) and HSP90,
were not affected by the T536I mutation. Overall, hu-
man IL-17A and IL-17F depend on ACT1 to mediate
protective mucocutaneous immunity. Moreover,
other ACT1-dependent IL-17 cytokines seem to be
largely redundant in host defense.
INTRODUCTION
Chronic mucocutaneous candidiasis (CMC) is characterized by
recurrent or persistent infections of the skin, nails, oral and
genital mucosae with Candida albicans, and sometimes by
staphylococcal skin infections (Glocker and Grimbacher, 2010;
Lilic, 2012; Puel et al., 2012; Alcais et al., 2010; Casanova and
Abel, 2013). Patients with inherited or acquired T cell immuno-676 Immunity 39, 676–686, October 17, 2013 ª2013 Elsevier Inc.deficiencies often suffer from CMC. Patients with autosomal
dominant (AD) hyper-immunoglobulin E (IgE) syndrome (HIES)
due to heterozygous loss-of-function mutations in STAT3
display CMC and a deficit of interleukin-17 (IL-17)-producing
T cells (Chandesris et al., 2012; de Beaucoudrey et al., 2008;
Ma et al., 2008; Milner et al., 2008; Minegishi et al., 2009; Renner
et al., 2008). Biallelic mutations of IL12B or IL12RB1 in patients
with Mendelian susceptibility to mycobacterial disease (MSMD)
can also lead to mild CMC, due to low proportions of IL-17-pro-
ducing circulating T cells (de Beaucoudrey et al., 2008; de Beau-
coudrey et al., 2010; Prando et al., 2013; C. Rodrı´guez-Gallego,
personal communication). Some patients with autosomal reces-
sive (AR) CARD9 deficiency and invasive fungal diseases also
have CMC and low proportions of circulating IL-17 T cells
(Drewniak et al., 2013; Glocker et al., 2009; A.P. and J.-L.C.
unpublished data). Finally, patients with autoimmune polyen-
docrinopathy type 1 syndrome (APS-1 also called APECED
syndrome) caused by biallelic mutations of AIRE have high titers
of neutralizing autoantibodies against IL-17A, IL-17F, and/or IL-
22 and suffer from CMC as the only infectious disease (Kisand
et al., 2010; Puel et al., 2010). Collectively, these experiments
of nature suggest that CMC is caused by impaired IL-17 immu-
nity, at least in the setting of these various conditions and,
possibly, in other clinical settings (Puel et al., 2012).
Patients genetically prone to CMC but normally resistant to
most other infections are considered to have CMC disease
(CMCD) (Canales et al., 1969; Kirkpatrick et al., 1971; Wells,
1970; Wells et al., 1972). The phenotype is not strictly limited
to CMC, because these patients often display other infections,
such as staphylococcal cutaneous disease, and even autoim-
mune manifestations, such as thyroiditis (Atkinson et al.,
2001; Liu et al., 2011b). Moreover, this condition is not
benign, because the patients can develop mucocutaneous
carcinomas and cerebral aneurysms (Leroy et al., 1989; Wil-
liamson, 1969). Complete AR IL-17RA deficiency and partial
AD IL-17F deficiency were the first two genetic etiologies of
Figure 1. A Kindred with CMCD and Auto-
somal-Recessive ACT1 Deficiency
(A) Pedigree of the kindred showing the segrega-
tion of the ACT1missense allele T536I. Individuals
for whom genetic status could not be evaluated
are indicated by ‘‘?’’. Generations are designated
by Roman numerals and individuals by Arabic
numerals.
(B) Manhattan plot showing the results for linkage
analyses. The Lodscore (log10) for each SNP is
plotted against chromosomal position (x axis) for
this kindred. The three genes carrying an unre-
ported missense mutation identified byWES in the
positive regions are indicated (see also Table S2).
(C) ACT1 DNA sequence electropherograms for
a healthy control and the four members of the
kindred for the region corresponding to the
missense mutation.
(D) Alignment of ACT1 orthologs from different
species.
(E) Schematic diagram of the ACT1 protein. The
gray box indicates the TRAF-interacting domain.
The helix-loop-helix (HLH), U3-box (U3-box), and
similar expression to fibroblasts growth factor and
IL-17R (SEFIR) domains are shown. The arrow
indicates the position of the missense mutation.
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ACT1 Mutations Underlie Mucocutaneous CandidiasisCMCD to be discovered (Puel et al., 2011). Heterozygous gain-
of-function (GOF) mutations of STAT1 were recently discovered
(Liu et al., 2011b; van de Veerdonk et al., 2011). They were
rapidly found in about half of CMCD patients (Hori et al.,
2012; Liu et al., 2011b; Romberg et al., 2013; Sampaio et al.,
2013; Smeekens et al., 2011; Takezaki et al., 2012; Uzel
et al., 2013; van de Veerdonk et al., 2011; Wang et al.,
2013b; A.P. and J.-L.C., unpublished data). These patients
also display impaired IL-17 T cell development, although the
mechanisms involved in this impairment remain unclear.
Together, these studies unambiguously indicate that IL-17A
and IL-17F are essential for protective mucocutaneous immu-
nity to C. albicans and, to a lesser extent, Staphylococcus
aureus. However, no genetic etiology has yet been identified
for about half the known patients with CMCD.
We studied two siblings with CMCD suffering from oral thrush
due to C. albicans and recurrent blepharitis due to S. aureus.
Both patients also displayed transient atopic dermatitis in in-
fancy. We deciphered the etiology of CMCD in these patients
by a genome-wide (GW) approach based on linkage analysis
and exome sequencing (Bogunovic et al., 2012; Boisson et al.,
2012; Bolze et al., 2010; Byun et al., 2010). We identified a bial-
lelic missense mutation (T536I) in the adaptor molecule ACT1
(TRAF3IP2). This missense mutation, located in the SEFIR,
impaired the homotypic interaction of ACT1with the IL-17 recep-
tors abolishing the response to IL-17A and IL-17F in fibroblasts
and to IL-17E in leukocytes. In contrast, the T536I allele did not
affect the interaction with other proteins (e.g., HSP90, HSP70,
or CD40), which is mediated by other domains. Fibroblastic cells
from healthy individuals for the homozygous D10N missense
polymorphism had a diminished but not abolished response to
IL-17A. IL-17A and IL-17F depend on ACT1 to mediate protec-
tive mucocutaneous immunity to C. albicans and S. aureus,
and the other IL-17 cytokines seem to be redundant in host
defense.RESULTS
Whole-Exome Sequencing in CMCD Patients Reveals a
Homozygous Missense Mutation of ACT1
We investigated a 30-year-old man (P1) born to consanguineous
Algerian parents (Figure 1A). At the age of eight years, he devel-
oped macrocheilitis associated with progressive chronic macro-
glossia. He has since suffered from recurrent oral candidiasis
affecting the mouth and tongue. His sister is 28 years old (P2)
and has suffered, since early childhood, from recurrent episodes
of bilateral blepharitis caused by S. aureus and folliculitis deca-
lvans (Quinquaud’s folliculitis) caused by S. aureus. She has
also had occasional episodes of oral thrush due to Candida albi-
cans and of onycomycosis due to Candida parapsilosis. Both
patients had infantile seborrheic dermatitis, which resolved
with local treatment within 6 weeks. Immunological investiga-
tions were unremarkable (case report and Table S1 available
online). A GW linkage (GWL) analysis by homozygosity mapping
in these two patients and their two healthy siblings was com-
bined with whole-exome sequencing (WES) for P2. Fifty-six ho-
mozygous regions, encompassing 93 Mb, were common to the
two affected siblings but were not found in the two unaffected
siblings (Figure 1B). Only three homozygous nonsynonymous
coding region variants (in C6ORF183, DOPEY2, and ACT1)
found in P2were not found in public databases or in our in-house
database (more than 10,000 chromosomes), indicating that the
frequency of homozygosity for these alleles is less than 108
(Table S2). The ACT1mutation was chosen for further investiga-
tion as a potential disease-causing gene due to its potential
impact on IL-17 pathways (Chang et al., 2006; Chang et al.,
2011; Qian et al., 2007). ACT-1 is recruited to IL-17RA, IL-
17RB, and IL-17RC and activates the NF-kB, MAPK, and
C/EBP pathways, leading to the induction of target genes in ker-
atinocytes, epithelial cells, and fibroblasts stimulated with IL-17
cytokines (Gaffen, 2009; Maitra et al., 2007; Onishi and Gaffen,Immunity 39, 676–686, October 17, 2013 ª2013 Elsevier Inc. 677
Figure 2. The T536I Mutation Impairs ACT1 Recruitment to the IL-17 Receptors
(A) ACT1 expression in EBV-B cells and SV-40 fibroblasts from P2. HEK293T cells transfected with WT-hACT1 or empty vector are shown as a control for the
specificity of anti-ACT1 antibody. GAPDH is used as a loading control.
(B–D) Immunoprecipitation of HA-tagged hACT1 in Act1/ cells reconstituted with WT-hACT1-HA or T536I-hACT1-HA. Cells are cotransfected with IL-17RA-,
IL-17-RB-, or IL-17RC-V5-tagged receptor chains. Immunoblotting analyses were performed with anti-HA or anti-V5 specific antibodies (n = 3).
(E) Homodimerization of ACT1. hACT1-HA was immunoprecipitated in HEK293T cells overproducing WT- or T536I-hACT1-HA and WT- or T536I-hACT1-FLAG.
The immunoblotting analysis was performed with specific anti-HA, anti-FLAG, or anti-HSP90 antibodies (n = 2).
(F) Heterodimerization of hACT1 and HSP90. WT- or T536I-hACT1-HA was immunoprecipitated in HEK293T cells overproducing WT- or T536I-hACT1-HA and
HSP90-FLAG. Immunoblotting analyses were performed with specific anti-HA, anti-FLAG or anti-HSP70 antibodies (n = 2) (see also Figure S1).
Immunity
ACT1 Mutations Underlie Mucocutaneous Candidiasis2010). P1 and P2 were found to be homozygous for the
c.1607C > T variant of ACT1, leading to production of the
p.T536I protein (Figure 1C). The intrafamilial segregation pattern
was consistent with an AR trait (Figures 1A–1C). The threonine
residue in position 536 has been conserved throughout evolution
(Figure 1D). Moreover, two computer programs (Polyphen, SIFT)
predicted the T536I mutation to be deleterious (Adzhubei et al.,
2013; Ng and Henikoff, 2003). The p.T536I mutation affects the
C-terminal part of the SEFIR domain, which is required for the
recruitment of ACT1 to IL-17RA, IL-17RB, IL-17RC, IL-17RD,
and IL-17RE (Figure 1E) (Gaffen, 2009; Mellett et al., 2012).
The T536I ACT1 Mutation Impairs Homotypic
Interactions with IL-17 Receptors
We assessed the amount of human ACT1 (hACT1) protein in
SV40-immortalized fibroblasts (SV-40 fibroblasts) and Epstein-
Barr virus-immortalized B cell lines (EBV-B cells) from four
controls, P2, and a patient with complete IL-17RA deficiency
(IL17RA/). All cells tested contained similar amounts of
hACT1 protein (Figure 2A). The cellular localization of T536I-
hACT1 in SV-40 fibroblasts from P2 is similar to that of
WT hACT1 in control fibroblasts (Figure S1A). The interaction678 Immunity 39, 676–686, October 17, 2013 ª2013 Elsevier Inc.between IL-17 receptors and ACT1 is dependent on the homo-
typic dimerization of two SEFIR domains. Although T536 is not
conserved in all protein paralogs harboring a SEFIR domain
(Novatchkova et al., 2003), we hypothesized that the T536I
missense mutation might impair the homotypic interaction of
ACT1 with IL-17 receptors. HEK293T cells were cotransfected
with WT-hACT1-HA or T536I-hACT1-HA and human IL-17RA-
V5, IL-17RB-V5, or IL-17RC-V5 vectors. Immunoprecipitation
with an anti-HA antibody showed that the T536I-hACT1-HA pro-
tein, unlike WT-hACT1-HA, was not bound to IL-17RA, IL-17RB,
or IL-17RC or was only weakly bound to these receptors (Figures
2B–2D). The SEFIR domain also plays an important role in ACT1
homodimerization (Liu et al., 2011a; Mauro et al., 2003). We thus
assessed the capacity of the T536I protein to homodimerize in
HEK293T cells, by cotransfecting these cells with WT-hACT1-
HA or T536I-hACT1-HA and WT-hACT1-FLAG or T536I-hACT1-
FLAG. Coimmunoprecipitation with the HA-antibody showed
that hACT1 proteins with and without the T536I substitution
were equally capable of homodimerization (Figure 2E; Fig-
ure S1B). ACT1 also binds to HSP90 via its N terminus (Wang
et al., 2013a). We assessed the impact of the T536I mutation on
this interaction in HEK293T cells, by cotransfecting these cells
Figure 3. The T536I ACT1 Mutation Abolishes the IL-17-Responsive Pathway in Fibroblasts
(A) IL-6 and GRO-a quantification in the supernatant of SV-40 fibroblasts from controls (C1, C2), P2, or IL-17RA-deficient patients, in response to IL-17A (10, 100,
and 1,000 ng/ml) or IL-1b (10 ng/ml); errors bars represent SEM (n = 3).
(B) Complementation of the fibroblasts of P2 with the WT ACT1 allele. IL-6 and GRO-a quantification in the supernatant of SV-40 fibroblasts from the control, P2,
or IL-17RA-deficient patients complemented (+ACT1) or not complemented with theWT ACT1 allele, after stimulation with IL-17A (100 ng/ml), TNF-a (2 ng/ml), or
both. Errors bars represent SEM (n = 3). Statistical analyses were performed by the unpaired t test method (NS, not significant; *p < 0.05; **p < 0.01) (see also
Figure S2).
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FLAG.Coimmunoprecipitationwith the anti-HAantibody showed
that the interaction between ACT1 and HSP90 or HSP70 was
intact (Figure 2F). Finally, T536I-hACT1 did not affect the stability
of ACT1-interacting proteins such as TRAF2, TRAF3, TRAF5,
TRAF6, SF2, or IL-17RA (Figures S1C and S1D). Thus, the
T536I missense mutation selectively prevents the homotypic
binding of ACT1 with at least three IL-17 receptor chains.
The Missense T536I Mutation of ACT1 Impairs the
Fibroblast Response to IL-17
ACT1 is an essential component of the IL-17A response pathway
and is required for the secretion of IL-6 and GRO-a in mice, via
activation of the IKK and MAPK pathways (Chang et al., 2006).
We first assessed the activation of the IL-17A response pathway
in Act1/ cells transfected with mock, WT-mAct1, or T517I-
mAct1 plasmids. Likewise, the expression of the orthologous
missense mouse Act1 (mACT1) allele (T517I) in Act1/ was
normal (Figure S2A). After stimulation with IL-17A, only WT-
mACT1 restored activation of the IKK (IkBa, NF-kB-P65) and
MAPK (JNK, ERK, P38) pathways (Figure S2B). We also
assessed the effects of T536I-hACT1, by investigating the IL-
17 pathways in SV40-fibroblasts from controls, P2, and an IL-
17RA-deficient patient (Puel et al., 2011). SV40-fibroblasts
from P2, like IL-17RA-deficient fibroblasts, produced no IL-6 or
GRO-a (also known as KC or CXCL1) in response to various
doses of IL-17A (Figure 3A) or IL-17F (Figure S2C), whereas con-
trol fibroblasts responded to even the lowest doses (10 ng/ml).
Cells from P2 and the IL-17RA-deficient patient responded nor-
mally to IL-1b. In a similar experiment in Act1/ cells, WT-
mACT1 induced the expression of Cxcl1 (encoding GRO-a),
Il6, and Csf2 (encoding GM-CSF), whereas T517I-mACT1 didnot (Figure S2D). We also assessed the activation of the NF-kB
pathways upon transfection of an NF-kB-driven luciferase
construct in SV-40 fibroblasts. Upon IL-17A, we found no lucif-
erase activity in hACT1-T536I-mutated or IL-17RA-deficient
fibroblasts, whereas controls cells responded (Figure S2E). We
then transduced SV40-fibroblasts from P2 with retroviruses ex-
pressing WT-hACT1. The stable production of WT-hACT1 in
the cells of P2 restored the induction of IL-6 and GRO-a produc-
tion in response to IL-17A to amounts similar to those observed
in the control (Figure 3B). No such increase in the production of
these molecules was observed after transduction with a mock
retrovirus. By contrast, the introduction of the WT-hACT1 allele
did not lead to the production of IL-6 andGRO-a in IL-17RA-defi-
cient cells (Figure 3B). ACT1 also acts in complex with SF2, to
prolong the half-life of messenger RNAs (mRNAs) upon costimu-
lation with IL-17A and tumor necrosis factor-a (TNF-a), sustain-
ing the production of cytokines, such as GRO-a and IL-6 (Sun
et al., 2011). We thus investigated indirectly this synergistic
effect by measuring the production of GRO-a and IL-6 in
response to costimulation with IL-17A and TNF-a. We used
hACT1-mutated fibroblasts from P2 transduced with an empty
or WT-hACT1-expressing virus. The P2 fibroblasts reexpressing
WT-hACT1 displayed synergic effects of IL-17A and TNF-a,
secreting more GRO-a and IL-6 than in response to either cyto-
kine alone (Figure 3B). This synergic effect was not detectable in
cells from P2 transduced with an empty vector or in IL-17RA-
deficient cells transduced with an empty or WT-hACT1-encod-
ing vector (Figure 3B). In Act1/ cells, the T517I-mACT1 did
not prolong the half-life of Cxcl1 and Il6 mRNA after treatment
with IL-17A and TNF-a (Figure S2E). Collectively, there is there-
fore a defect of transcriptional upregulation of the IL-17 target
genes, due to impaired NF-kB activation in the fibroblasts ofImmunity 39, 676–686, October 17, 2013 ª2013 Elsevier Inc. 679
Figure 4. The D10N ACT1 Polymorphism Impairs but Does Not Abolish the IL-17-Responsive Pathway in Fibroblasts
(A) GRO-a and (B) IL-6 quantification in the supernatant of SV-40 fibroblasts from controls, D10N individual, P2, and an IL-17RA-deficient patient, upon stim-
ulationwith IL-17A (500 ng/ml), TNF-a (2 ng/ml), or both (IL-17A+TNF-a) or IL-1b (10 ng/ml); errors bars represent SEM (n = 7). Statistical analyses were performed
by the unpaired t test method (NS, not significant; *p < 0.05; **p < 0.01).
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of ACT1.
The Missense D10N Polymorphic Allele of ACT1 Is
Hypomorphic, but Not Null
Recent studies have investigated the polymorphic D10N allele
of human ACT1 (rs33980500), which is associated with an
increased risk of psoriasis and psoriatic arthritis (Ellinghaus
et al., 2010; Hu¨ffmeier et al., 2010). Studies based on overex-
pression in HEK293T cells or in Act1/ cells suggest that this
allele is loss of function, at least for the interaction with TRAF-6
and the activation of the IL-17A-dependent gene expression
(Hu¨ffmeier et al., 2010; Wang et al., 2013a). Due to the frequency
of the D10N allele in most human populations studied (MAF
about 0.09), about 0.8%of the population worldwide is predicted
to be homozygous. If this were a null mutation, abolishing cellular
responses to IL-17 in particular, the high frequency of homozy-
gotes would not be consistent with the rarity of CMCD (about
1/100,000). We investigated this apparent discordance by
testing an individual without CMCD carrying two copies of the
polymorphic D10N allele. We evaluated the response of SV40-
fibroblasts from this individual to IL-17A. The cells from the indi-
vidual with the D10N allele responded weakly to IL-17A, with low
but detectable GRO-a and IL-6 induction (Figures 4A and 4B).
Moreover, costimulation with IL-17A and TNF-a was synergistic
in the cells of the individual with the D10N allele, contrasting with
the complete absence of a synergistic response in cells from P2
and the IL-17RA-deficient patient. These findings demonstrate
that the human D10N ACT1 allele is hypomorphic, but not null,
for cellular responses to IL-17A, alone or in combination with
TNF-a. This result reconciles the frequency of homozygosity
for the D10N allele in the human population and the rarity of
CMCD. It also highlights the uniqueness of the T536I allele,
which is a true null allele for IL-17 responses.680 Immunity 39, 676–686, October 17, 2013 ª2013 Elsevier Inc.The T536I Missense Mutation of ACT1 Impairs the IL-17
Signaling Pathway in Leukocytes
Some IL-17 cytokines also act on leukocytes and contribute to
the differentiation of certain cytokine-producing T cells. IL-17E
(also known as IL-25) has recently been shown to signal through
IL-17RA and IL-17RB, leading to the differentiation of CD4+
T cells into IL-5- and IL13-producing cells in mice (Rickel et al.,
2008). We investigated the IL-17E response pathway in PBMCs
from controls, P1, P2, and healthy members of their family.
Thymic stromal lymphopoietin (TSLP)-stimulated PBMCs have
been shown to produce IL-5 and IL-13 in presence of IL-2 or
IL-17E (Rickel et al., 2008). Control PBMCs produced about
five times more IL-5 in response to costimulation with IL-2 and
IL-17E than in response to each cytokine individually (Figure 5A).
By contrast, cells from P1 and P2 were unable to respond syner-
gistically to the combination of IL-2 and IL-17E, whereas IL-2
alone induced IL-5 production. The patients’ healthy sisters
(II.2 and II.3) responded normally to IL-17E, whereas the IL-
17RA-deficient patient did not (Figure 5A). Thus, the T536I
missense mutation of ACT1 also impaired IL-17 responses in
T cells. Act1/ mice have higher proportions of IL-17A-, IL-
17F-, IL-22-, and IFN-g-producing T cells than control mice,
but the underlying mechanisms are unknown (Qian et al., 2007;
Wang et al., 2013a). We therefore carried out flow cytometry to
investigate, ex vivo and in vitro, the proportion of IL-17A-, IL-
22-, and IFN-g-producing CD3+ T cells. P1 had higher propor-
tions of IL-17A-producing (9.6%) and IL-22-producing (7.8%)
T cells ex vivo than all 85 healthy controls tested (Figure 5B),
which is consistent with findings for the mouse model (Qian
et al., 2007). By contrast, this patient had normal proportions
of IFN-g-producing T cells. Moreover, T cells from P1 and P2
cultured with IL-2, IL-17E, or both, and restimulated by incuba-
tion with PMA/ionomycin for 12 hr, also contained higher propor-
tions of IL-17A-producing T cells than T cells from the controls,
Figure 5. The T536I ACT1 Mutation Abolishes the IL-17E Response
in T Cells
(A) PBMCs from controls, patients (P1, P2), and healthy relatives (II.2, II.3) and
from an IL-17RA-deficient patient were cultured in TSLP for 24 hr, harvested,
and restimulated with IL-2 and IL-17E for an additional 72 hr. IL-5 concen-
trations in the culture supernatants were determined by ELISA. IL-5 concen-
trations were normalized to 100 pg/ml upon IL-2 stimulation. Errors bars
represent SEM (n = 2).
(B) Percentages of IL-17A+-, IL-22+-, and IFN-g+-producing CD3+ cells, as
determined by flow cytometry, in nonadherent PBMCs activated by incubation
for 12 hr with PMA and ionomycin. Each symbol represents a value from a
healthy control individual (black circles), P1 (black rectangle), or an IL-17RA-
deficient patient (black upside-down triangles) (see also Figure S3).
Figure 6. The T536I-ACT1 Mutation Does Not Perturb the CD40-
Responsive Pathway
(A) Immunoprecipitation of ACT1-HA in HEK293T cells reconstituted with
WT-hACT1-HA or T536I-hACT1-HA. Cells were cotransfected with human
CD40-FLAG. Immunoblotting analyses were performed with anti-HA, anti-
TRAF3, or anti-FLAG specific antibodies.
(B) Activation of CD40 pathways in EBV-B cells from P2. Immunoblotting
analysis was performed with antibodies against phospho-IKKa and phospho-
IKKb (P-IKKs), IkBa, and phospho-p42 and phospho-p44 (P-p42-p44) in
CD40L-stimulated EBV-B cells from the control or P2 (n = 2).
Immunity
ACT1 Mutations Underlie Mucocutaneous Candidiasisthe two healthy siblings, and the IL-17RA-deficient patient (Fig-
ure S3). By contrast, the proportions of IFN-g- and IL-13-produc-
ing T cells were normal (Figure S3). Despite the large proportion
of IL-17-producing T cells in the two siblings with ACT1 muta-
tions and CMCD, these individuals had no IL-17 response and
were not protected against C. albicans. The expansion of the
IL-22-producing T cell population does not seem to be sufficient
to control CMC and seems to have no other detectable clinical
consequences.The T536I Missense Mutation of ACT1 Does Not Impair
the CD40 Response Pathway
ACT1 has also been reported to regulate the CD40 and BAFF-R
pathways (Qian et al., 2004). Act1/ mice (BALB/c/129 back-
ground) display enhanced B cell responses to CD40L and
BAFF. As mACT1 has been shown to be recruited to TRAF3
via its TRAF-interacting domain (Qian et al., 2004), it has also
been suggested that ACT1 inhibits CD40 and BAFF-R through
interaction with TRAF3 (Qian et al., 2004). We thus assessed
the impact of the T536I mutation on this interaction in
HEK293T cells cotransfected with hCD40-FLAG and hACT1-
HA with and without the T536I mutation. The T536I mutation
did not abolish the interaction of ACT1 with the costimulatory
molecule CD40 (Figure 6A). Moreover, the time course of IKK
and IkBa phosphorylation upon CD40L stimulation was similar
in EBV-B cells from controls (C1 and C2) and fromP2 (Figure 6B).
These data, obtained with EBV-B cells in vitro, are consistent
with the lack of an overt B cell phenotype in vivo. Indeed,
Act1/ mice have hypergammaglobulinemia, with high serum
concentrations of IgG, IgA, and IgE. Similarly, serum IgG
concentrations were high in P1 and P2 (>17 g/l), but similar to
those in patients with chronic infections. By contrast, serumImmunity 39, 676–686, October 17, 2013 ª2013 Elsevier Inc. 681
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S1). Likewise, another independent Act1/ mouse line in
another genetic background (129/Sv) presented no overt B cell
phenotype (Claudio et al., 2009). Overall, the missense T536
mutation in ACT1 did not significantly enhance the CD40 and
BAFF-R pathways in the patients’ B cells. Thus this mutation,
affecting the SEFIR domain, selectively impairs the IL-17
response pathway in leukocytes, such as T cells, and in nonhe-
matopoietic cells, such as fibroblasts.
DISCUSSION
We identified biallelic mutations of ACT1 as a new genetic etiol-
ogy of CMCD in two patients. The morbid T536I mutation dis-
rupts the interaction of ACT1 with IL-17 receptors, but not with
CD40 and BAFF-R. This mutation affects the SEFIR domain,
which has been characterized and modeled with computer soft-
ware (Liu et al., 2011a; Zhang et al., 2013). Deletion of the termi-
nal part of the mACT1 SEFIR domain, containing the amino acid
corresponding to the T536 residue of the human protein, did not
affect the interaction of ACT1 with IL-17 receptors (Liu et al.,
2011a). However, introduction of the orthologous missense
mutation into mAct1 (T517I) abolished the induction of cytokines
in response to IL-17A stimulation (this report). These data
therefore suggest that the human T536 and mouse T517 resi-
dues are essential for the conformational structure of the SEFIR
domain or that their replacement by an isoleucine residue dis-
rupts the activity of this domain. The effects of this mutation
also strongly suggest that ACT1 homodimerization and ACT1-
IL-17R interaction involve different regions of the SEFIR domain.
Indeed, the T536I mutation leads to a loss of homotypic interac-
tion with members of the IL-17 receptor family but does not
impair homodimerization.
This observation explains the patients’ CMCD phenotype.
Indeed, patients with AR IL-17RA or AD IL-17F deficiencies suf-
fer from CMCD due to impaired IL-17A- and IL-17F-mediated
immunity (Puel et al., 2011) and patients heterozygous for GOF
STAT1 alleles also display CMCD due to impaired IL-17 immu-
nity (Liu et al., 2011b; A.P. and J.-L.C., unpublished data; Rom-
berg et al., 2013; Smeekens et al., 2011; Takezaki et al., 2012;
van de Veerdonk et al., 2011). Biallelic mutations of ACT1 there-
fore define the fourth genetic etiology of CMCD and the second
affecting the IL-17 response pathway. In both mice (Qian et al.,
2007) and humans (this report), ACT1 deficiency leads to expan-
sion of IL-17- and IL-22-producing T cell populations. Themech-
anism underlying this phenotype is unknown. High amounts of
IL-17 are ineffective in the absence of ACT1, and IL-22, the func-
tion of which is unknown in humans, does not seem to compen-
sate for the lack of IL-17 responses. The clinical phenotypes of
IL-17RA and ACT1 deficiencies are indistinguishable, at least
in terms of the CMC and staphylococcal disease of the patients.
The ACT1-T536I-mutated patients also developed mild and
transient infantile seborrheic dermatitis, a relatively common
skin disease. Among the possible causes of infantile seborrheic
dermatitis, infection byMalassezia furfur andStaphylococci have
both been suspected to be causal (Bieber, 2008). This condition
is rare in developed countries, thanks to the improvement of
hygiene (Kallioma¨ki et al., 2001). The mild infantile dermatitis
seen in the ACT1-T536I-mutated patients might perhaps also682 Immunity 39, 676–686, October 17, 2013 ª2013 Elsevier Inc.result, at least in part, from the expansion of the IL-22 T cell pop-
ulation, as suggested by findings in humans (Nograles et al.,
2009) and mice (Wang et al., 2013a). The lack of infantile derma-
titis in IL-17RA-deficient patients, whose IL-22-producing T cells
are not expanded, also favors this hypothesis (Puel et al., 2011).
Too few IL-17RA-deficient patients have been diagnosed yet to
draw firm conclusions, however. Two strains of Act1/ mice
were found to have atopic dermatitis (Matsushima et al., 2010;
Qian et al., 2004, 2008; Wang et al., 2013a); this was not
observed in a third strain (Claudio et al., 2009). The ACT1-
T536I-mutated patients did not display any atopy.
We also found that the D10N variant of ACT1 was hypomor-
phic, but not null, for cellular responses to IL-17, consistent
with its high frequency in human populations and the rarity of
CMCD. There is an apparent discrepancy between our data
and others (Ellinghaus et al., 2010; Hu¨ffmeier et al., 2010;
Wang et al., 2013a), which proposed that this psoriasis suscep-
tibility allele is functionally null. This discrepancy might be ex-
plained by the presence of two ACT1 isoforms in humans, a short
form and a long form, which contains nine additional amino acids
at the N terminus; there is only one short isoform of Act1 in
mouse. Only the short isoform (D10N) has been demonstrated
to be null. The long isoform (D19N) might be functional (X.L.,
unpublished data). Further studies are required to clarify this
matter. The two patients homozygous for the T536I allele of
ACT1 do not display psoriasis suggesting that impaired IL-17 ac-
tivity is not sufficient to trigger psoriasis. In any case, ACT1 is
required for IL-17A and IL-17F mucocutaneous immunity to
C. albicans and S. aureus in humans.
Other IL-17 cytokines have been implicated in immunity. IL-
17B, IL-17C, and IL-17E have been shown to bind to IL-17R
family members (IL-17RA, IL-17RB, IL-17RE) requiring ACT1,
for signaling in mice (Gaffen, 2009). No data are available for
IL-17D. The cells of patients with ACT1 mutations are probably
unable to respond to IL-17C because the mutated ACT1 does
not bind to IL-17RA (Chang et al., 2011). The cells of the patients
(this report) failed to respond to IL-17E, and the response to this
cytokine is IL-17RB-dependent in mice (Rickel et al., 2008).
These cells are probably also unable to respond to IL-17B, which
also binds IL-17RB in human cells (Shi et al., 2000). Collectively,
the observation that IL-17RA-deficient and ACT1-mutated
patients display CMC as their only major infection suggests
that IL-17B, IL-17C, IL-17D, and IL-17E play largely redundant
roles in host defense in humans. This is intriguing because IL-
17C and IL-17E have been implicated in immunity to worms
and bacteria in mice. For example, Il17re/mice (unresponsive
to IL-17C) die prematurely after Citrobacter rodentium infection,
highlighting the role of IL-17C in intestinal immunity (Chang et al.,
2011; Ramirez-Carrozzi et al., 2011; Song et al., 2011). More-
over, Il25/ mice (lacking IL-17E) are more susceptible to
Nippostrongylus brasiliensis and Trichuris muris than control
mice (Fallon et al., 2006; Owyang et al., 2006; Zhao et al.,
2010). Act1/ and conditional K18creAct1/ mice (in which
ACT1 is deleted in epithelial cells) are also more susceptible to
infection with Nippostrongylus brasiliensis (Kang et al., 2012).
ACT1 plays a broader role than IL-17RA in IL-17 responses,
but patients with ACT1 mutations do not suffer from a broader
range of infections than patients with IL-17RA and IL-17F
deficiencies (with impaired IL-17A and IL-17F immunity) (Puel
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of patients before we can draw any firm conclusions, but our
observations suggest that IL-17B, IL-17C, IL-17D, and IL-17E
are largely redundant. An alternative, intriguing possibility is
that these human cytokines can also signal via ACT1-indepen-
dent pathways.
EXPERIMENTAL PROCEDURES
Sample Collection
This study was conducted in accordance with the Helsinki Declaration, with
informed consent obtained from each patient or the patient’s family. The
study was approved by the local ethics committee of Necker-Enfants
Malades Hospital, Paris, France and The Rockefeller University Hospital,
New York, USA.
Genetic Analysis
Genotyping and Linkage Analysis
Four members of this Algerian family were genotyped with the Affymetrix
Genome-wide SNP 6.0 array. Genotype calling was achieved with Affyme-
trix Power Tools (http://www.affymetrix.com/partners_programs/programs/
developer/tools/powertools.affx) for the four family members. We discarded
monomorphic SNPs, SNPs with a call rate lower than 100%, and SNPs pre-
senting more than one Mendelian inconsistency in the family. SNPs were
further filtered with population-based filters (Purcell et al., 2007). We then
used about 110,347 high-quality SNP markers to carry out linkage analysis,
assuming autosomal recessive inheritance with complete penetrance
(homozygosity mapping). Parametric multipoint linkage analysis was carried
out with the Merlin program (Abecasis et al., 2002). The Algerian family
founders and HapMap CEU trios were used to estimate allele frequencies
and to define linkage clusters, with an r2 threshold of 0.4.
Massively Parallel Sequencing
Genomic DNA (3 mg) extracted from the peripheral blood cells of the patient
was sheared with a Covaris S2 Ultrasonicator (Covaris). An adaptor-ligated
library was prepared with the Paired-End Sample Prep kit V1 (Illumina). Exome
capture was performed with the SureSelect Human All Exon kit (Agilent Tech-
nologies). Single-end sequencing was performed on an Illumina Genome
Analyzer IIx (Illumina), generating 72 base reads.
Sequence Alignment, Variant Calling, and Annotation
The sequences were aligned with the human genome reference sequence
(hg19 build) with BWA aligner (Li and Durbin, 2009). Downstream processing
was carried out with the Genome Analysis Toolkit (GATK) (McKenna et al.,
2010) SAMtools (Li et al., 2009), and Picard Tools (http://picard.sourceforge.
net). Substitution calls were made with a GATK UnifiedGenotyper, whereas
indel calls were made with a GATK IndelGenotyperV2. All calls with a read
coverage %23 and a Phred-scaled SNP quality of%20 were filtered out. All
the variants were annotated with the GATK Genomic Annotator.
Cell Lines, Immortalization, and Complementation
Control and patient-derived fibroblasts were immortalized by transfection with
a plasmid containing the simian virus 40 large T antigen gene. Transformed cell
lines were grown in DMEM (GIBCO#10566) supplemented with 10% fetal
calf serum (GIBCO#16000). The IL17RA/ fibroblasts used have been
described elsewhere (Puel et al., 2011). ACT1mRNA was reverse transcribed,
amplified, and inserted into the retroviral vector pMSCV (Clontech). Infectious
viral particles were produced by cotransfecting GP2-293 packaging cells with
pVSV-G and the retroviral expression vector pMSCV-hACT1 or an empty vec-
tor (Clontech). Viral particles were collected between 48 and 72 hr after trans-
fection and were used to infect SV40-transformed fibroblasts. Infected cells
were selected on medium supplemented with 0.4–0.8 mg/ml puromycin.
Cell Lysis, Immunoprecipitation, and Immunoblotting
Cells were lysed in a lysis buffer containing 30 mM Tris-HCl pH 7.5, 120 mM
NaCl, 2 mM KCl, 1% Triton X-100, and 2 mM EDTA supplemented with prote-
ase inhibitor cocktail (Complete, Roche) and phosphatase inhibitor cocktail
(PhoStop, Roche). Laemmli buffer supplemented with DTT was added to clear
supernatants. For immunoprecipitation, cells were lysed in lysis buffer (0.5%Triton X-100, 20 mM HEPES [pH 7.4], 150 mM NaCl, 12.5 mM b-glycerophos-
phate, 1.5 mMMgCl2, 10 mMNaF, 2 mM dithiothreitol, 1 mM sodium orthova-
nadate, 2 mM EGTA, 20 mM aprotinin, 1 mM phenylmethylsulfonyl fluoride).
Cell extracts were incubated with 1 mg of the appropriate antibodies overnight
at 4C with 20 ul of protein A Sepharose beads. After incubation, beads were
washed four times with lysis buffer. Samples were separated by SDS–PAGE
and proteins were transferred onto a PVDF membrane. The membrane was
blocked in TBS supplemented with 0.1% Tween 20 and 5% skimmed milk
powder and incubated with the primary antibody, followed by the appropriate
horseradish peroxidase-conjugated secondary antibody. Immunoreactive
proteins were visualized by enhanced chemiluminescence.
Luciferase Assays
For NF-kB-dependent reporter assays, SV40-transformed fibroblasts were
transiently transfected with the NF-kB-dependent firefly luciferase plasmid
pGL4.32 (Promega) and the Renilla luciferase plasmid as internal control
with Lipofectamine LTX reagent (Invitrogen). After 24 hr, cells were stimu-
lated with TNF or IL-1b for 4 hr and luciferase activities were assessed with
the dual luciferase assay kit (Promega).
PBMC Culture
Frozen PBMCswere cultured in the presence of 100 ng/ml thymic stromal lym-
phopoietin (R&D Systems, 1398-TS-010/CF0) in X-VIVO 15 (Lonza) plus 5%
human AB serum (Lonza), as previously described (Rickel et al., 2008). PBMCs
were collected, washed, and resuspended at a density of 43 106 cells/well in
48-well plates with a final volume of 0.5 ml/well, in the presence of 10 ng/ml
recombinant human IL-2 (R&D Systems) and 10 ng/ml recombinant human
IL-17E (R&D Systems). After 3 days, the amount of IL-5 secretion was deter-
mined with ELISA kits (DY205, R&D Systems).
Flow Cytometry
PBMCs cultured as described above were then stimulated with
PMA+ionomycin (107 M/105 M) or left unstimulated. Concomitantly to stim-
ulation, protein transport was blocked with GolgiStop and GolgiPLug (BD).
Cells were stained with anti-CD3 (BD, #560366) and anti-CD19 (BD,
#340951) antibodies for cellular phenotyping and with Aqua Live/Dead (Invitro-
gen) to exclude dead cells. The cells were fixed and permeabilized (BD,
#554722) and then stained with antibodies against IL-17A (eBioscience,
#53-7179-42), IL-13 (Biolegends, #501907), and IFN-g (BD, #559326). Stained
PBMCs were captured by flow cytometry with a BD LSRII flow cytometer and
FACS Diva software. The data were analyzed with FlowJo (Tree Star).
Statistical Analysis
Data were analyzed with Student’s t test with GraphPad Prism (GraphPad
Software), and p < 0.05 was considered statistically significant.
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